[Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Efficacy and safety of long-term treatment with an LH-RH agonist, TAP-144-SR were studied in premenopausal patients with advanced or recurrent breast cancer. The drug was given sc every 4 week at the dose of 3.75 or 7.5mg. The best objective response rates were 37.0% (17/46) in 3.75mg group, 30.6% (15/49) in 7.5mg group, respectively. The median duration of 12 PR patients in 3.75mg group was 280 (range: 84-830+) days. Serum estradiol level was maintained at < 30pg/ml in most patients given 3.75mg or 7.5mg as scheduled. There was no adverse reactions specific to the longterm administration subsequent to the foregoing 12-week administration study in both dose groups. In conclusion, TAP-144-SR is expected to be one of the first line therapies for patients with premenopausal breast cancer.
Taguchi
T
T
Japan Society for Cancer Chemotherapy, Dept. of Surgery, Center for Adult Diseases, Osaka.
Koyama
H
H
Yayoi
K
K
Wada
T
T
Takatsuka
Y
Y
Sonoo
H
H
Morimoto
K
K
Tominaga
T
T
Abe
R
R
Enomoto
K
K
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002979:Climacteric / Q000187:drug effects; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017697:Premenopause
D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D016729:Leuprolide